The startup develops a biopharmaceutical treatment that utilizes pharmacotherapy to reduce alcohol consumption in patients with alcohol use disorder. This approach aims to enhance patients' quality of life while decreasing the associated health risks and societal costs of alcohol abuse.
Funding
$3.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Alcohol Use Disorder (AUD) affects millions globally, leading to increased mortality, morbidity, and significant socio-economic costs. Current pharmacological and non-pharmacological treatments for AUD have limited efficacy, leaving a substantial unmet need for more effective interventions to reduce alcohol cravings and consumption.
Solution
Sobrera Pharma is developing SO-001, a combination pharmacotherapy designed to reduce alcohol intake in patients with moderate to severe AUD. SO-001 consists of two pharmaceutical products that work synergistically to restore dopamine levels in the brain's reward system. By mildly stimulating neuronal firing and dopamine release while inhibiting its re-uptake, SO-001 aims to produce a slow, sustained increase in dopamine levels, reducing the desire to consume alcohol. A Phase 2 clinical trial demonstrated a statistically significant reduction in alcohol consumption, measured by both an objective alcohol biomarker (B-PEth) and self-reported heavy drinking days.
Target Audience
The primary target audience includes individuals diagnosed with moderate to severe Alcohol Use Disorder (AUD) who are seeking pharmacological interventions to reduce alcohol consumption and improve their quality of life.
Features
- Combination therapy targeting dopamine neurotransmission in the brain's reward system
- Composed of two active pharmaceutical ingredients with complementary mechanisms of action
- Designed for a slow, sustained increase in dopamine levels
- Demonstrated statistically significant reduction in alcohol consumption in a Phase 2 clinical trial
- Reduction in alcohol consumption was measured by Phosphatidylethanol (B-PEth) levels
- Reduction in alcohol consumption was measured by self-reported heavy drinking days
- Phase I study completed, evaluating the pharmacokinetic profile of the formulation